Combination therapy can delay resistance of lung cancer cells
A specific genetic alteration, known as an ALK fusion, drives non-small cell lung cancer in some patients. This abnormality leads to excessive activity of the ALK protein, a key cancer promoter. These tumors can be treated ...
Apr 16, 2024
0
26